



Syndicated Thought Leader Insight

Thought Leader Insight & Analysis Report Diabetes/Obesity Q4 2010

Therapeutic Class:	Metabolic Disorders
Focus Area:	Diabetes/Obesity
Specialty/Location:	Endocrinologists/ Europe, N. America
Number of Interviews:	6
Number of Pages:	132
Publication Date:	November 2010
Principal Authors:	Tricia L. Hanlon Kim Grant Gerald Asin, M.D. Jeffrey D. Berk, Ph.D., MBA
Product Code:	MDOQ410-13
Pricing:	\$7,000
Order Info:	www.medpredict.com or call (513) 271-1924

Abstract: MedPredict interviewed N. American and European thought leaders to identify the most promising candidates in clinical development, as well as explore unmet needs. Drug classes discussed include biguanides (metformin), DPP4 inhibitors, GLP-1 agonists, PPAR, secretagogues, SGLT2, GPR-119, insulins and (briefly) amphetamines.

Some of the questions addressed by this panel include:

- What are the advantages and disadvantages of GLP-1 agonists vs. DPP4 inhibitors?
- What will be the impact of the FDA's complete response letter to Lilly/Amylin requesting additional Bydureon data uptake of Novo Nordisk's Victoza?
- What are Victoza's advantages vs. Lilly/Amylin's Byetta?
- Is the increased pancreatitis seen with GLP-1's due to mechanism of action, or related to the disease condition?
- What will be one of the keys to physician acceptance of SGLT2 inhibitors?
- How do panelists distinguish between Merck's Januvia and BMS/AZ's Onglyza?
- How will Kombiglyze XR (a once-daily form of saxagliptin just approved by FDA) or Boehringer Ingelheim's Ondero (linagliptin, expected filing 4Q 2010) impact prescribing in the DPP4 class?
- What is the outlook for MannKind's inhaled insulin product, Afrezza? Will their Technosphere delivery system overcome the negative impact on lung function that caused Pfizer's Exubera to be discontinued?

Full transcripts of six qualitative interviews with endocrinologists are included with this report.

Companies/Drugs Discussed in this Report:

Company	Generic	Brand
	metformin	
	sulfonylurea	
Arena	APD597 (JNJ-38431055)	
AstraZeneca/Bristol-Myers Squibb	saxagliptin dapagliflozin	Onglyza / Kombiglyze XR
Boehringer Ingelheim	linagliptin	Ondero
Generex / Shreya	insulin	Oral-Lyn
GlaxoSmithKline	albiglutide rosiglitazone	Syncria Avandia
J&J / Depomed	canagliflozin	
Lilly / Amylin	exenatide	Byetta / Bydureon
Lilly	LY2189265 LY2428757	
Lilly / Takeda	pioglitazone	Actos
Lexicon	LX-4211	
MannKind	MKC-253 Technosphere® inhaled insulin	Afrezza
Merck	sitagliptin MK-0431C monthly GLP-1 depo	Januvia / Janumet / Depo
Novo Nordisk	insulin liraglutide NN1250 NN9924	Levemir Victoza Degludec
Oramed	exenatide oral	
Pfizer / Nektar	insulin	Exubera
Roche / Ipsen	taspoglutide	
Sanofi-Aventis	lixisenatide (AVE-0010) insulin glargine	Lantus
Transition Therapeutics	TT-223	
Vivus	phentermine / topiramate	Qnexa

Table of Contents

Executive Summary	4
Report Highlights	5
Key Findings	15
Diabetes and Death From Cardiovascular Causes	15
Biguanide	16
Metformin	16
Incretins	19
DPP4	19
Januvia / Janumet / Depo (sitagliptin; Merck / Depomed)	19
MK-0431C (pioglitazone + sitagliptin; Merck)	26
Onglyza / Kombiglyze XR (saxagliptin; BMS/AZ)	27
Ondero (linagliptin; Boehringer Ingelheim)	28
GLP-1	30
Byetta (exenatide; Amylin/Lilly)	33
Bydureon (exenatide LAR; Lilly/Amylin/Alkermes)	38
tasoglutide (Roche / Ipsen)	40
Victoza (liraglutide; Novo Nordisk)	40
Syncria (albiglutide; GlaxoSmithKline)	46
Lixisenatide (AVE-0010; Sanofi-Aventis)	47
LY2189265 (Lilly)	48
LY2428757 (Lilly)	48
GLP-1 Depo (Merck)	49
ORMD-0901 (exenatide oral; Oramed)	49
MKC253 (Human GLP-1; MannKind)	50
NN9924 (Novo Nordisk / Emisphere)	50
PPAR	50
Actos (pioglitazone; Takeda/Lilly)	50
Avandia (rosiglitazone; GSK)	53
Secretagogues	55
Sulfonylureas	55
SGLT2	59
dapagliflozin (Bristol-Myers Squibb / AstraZeneca)	63
canagliflozin (J&J / Depomed)	66
LX-4211 (Lexicon)	67
GPR-119 (Gene Protein Coupled Receptor)	68
APD597 (JNJ-38431055; Arena / ex-J&J)	68
Insulins	69
Levemir (Novo Nordisk)	69
Degludec (NN1250; Novo Nordisk)	70
Lantus (Sanofi-Aventis) vs. Levemir (Novo Nordisk)	71
Inhaled: Exubera (Pfizer / Nektar)	72
Lilly Spinhaler	74
Afrezza (Technosphere® Inhaled Insulin System; Mannkind)	75
Oral-Lyn (Generex / Shreya)	80
ORMD-0801 (Oramed / Sanofi-Aventis)	82

Amphetamine.....	82
Qnexa (phentermine / topiramate; Vivus).....	82

Thought Leader Discussions 84

Interview BJE02474.....	84
Interview BJE02473.....	94
Interview BJE02472.....	103
Interview BJE02469.....	110
Interview BJE02486.....	119
Interview BJE02471.....	125